2^nd Annual Virtual Biopharma Comms Forum: Day 2

Josh Deutchman has provided writing, communications, change management and creative support across a who’s who of industries…..financial/insurance, high-tech, nonprofit, pharmaceutical, and government. Clients and employers include Wells Fargo, Edward Jones, Marsh, AIG, Pfizer, NASA, and the U.S. EPA.

With a sustained focus on the conceptual and the strategic, Josh translates uncertainty into a narrative that people can understand, believe in, and act on, so that when foundational change is complete, the organization has a powerful and positive story to tell.

Josh received a BA from the University of California, Berkeley, and an MFA in Creative Writing from American University. He lives in New York’s Lower Hudson Valley.

Megan Humphreys serves as Vice President of Corporate Communications for Evommune. She has nearly 20 years of experience in corporate affairs and communications across biotechnology, pharmaceutical, and other highly regulated industries. Prior to joining Evommune, Megan was Head of Corporate Affairs and Public Affairs at RayzeBio (acquired by Bristol Myers Squibb), and Head of Communications at Mirati Therapeutics (acquired by Bristol Myers Squibb), guiding the company through the launch of KRAZATI®, significant clinical and corporate milestones, and its acquisition by Bristol Myers Squibb. Earlier in her career, she held senior communications and public affairs roles at Spectrum Science, Signal Group and other agencies, advising biotechnology and pharmaceutical companies across stages of development. She also founded and led Convé Communications, a boutique life sciences communications consultancy. Megan earned her Masters in Public Relations and International Relations from the S.I Newhouse School of Public Communications and the Maxwell School of Citizenship and Public Affairs at Syracuse University.

Eric McKeeby is Head of Corporate Communications at insitro, a $2.57B AI drug discovery company backed by a16z, ARCH, BlackRock, Google Ventures, and Temasek. He rejoined in 2025 to scale and agentify communications after previously launching the function. Since then, he has driven 3-4x social and earned growth, brand modernization, and a sustained global dialogue on artificial intelligence and causal biology in advance of insitro’s AI-discovered and designed MASH and ALS drug candidates entering first-in-human trials. Recently, he launched Deep Phenotype in Substack’s top 1%, with a manifesto from founder/CEO Daphne Koller.

As an Edelman VP, he created award-winning campaigns for Abbott, Merck, Novocure, and GE Healthcare, as well as for two Michelle Obama initiatives. As Head of Marketing & Communications at the Parker Institute for Cancer Immunotherapy, he united a prestigious research network, agentified workflows, and synthesized science for legislators and donors, supporting 17 venture companies. As the Regeneron Genetics Center’s Head of Communications & Marketing, he built a standalone global brand. At Ancestry, he launched AncestryHealth during peak pre-pandemic DNA zeitgeist and recruited ~1M customers during lockdown to volunteer DNA and phenotypic data for history’s largest COVID genomics study.

Eric received a B.A. in Political Science from Rollins College and an M.A. from NYU’s Tisch School of the Arts, where he prototyped social networks and interactive storytelling platforms for cancer communities. A 30-year lymphoma survivor, he volunteers on the regional executive leadership team for Blood Cancer United and is writing a book, Surviving the Survival. He served in the U.S. Army as a post-9/11 photojournalist in the Middle East, Africa, and at sea.

Bernadette Murdoch is Head of Corporate and External Affairs for R&D, Business Development and Enabling Functions at CSL. She leads communications across R&D and business development, as well as key enterprise functions including people communications. An experienced corporate affairs leader, Bernadette specialises in translating complex science, strategy and business priorities into clear and compelling narratives for a wide range of stakeholders. She is particularly passionate about communicating innovation and the role that partnerships, science and people play in creating meaningful value for patients and society.

Jessica Freifeld is an entrepreneurial communications leader with 17+ years of experience driving high-impact storytelling, executive visibility, and strategic reputation-building for healthcare companies and leaders. Her career spans global public health, health tech and biotech, and she has deep expertise in elevating narratives around some of the industry’s most transformative areas, including artificial intelligence (AI) and digital health.

As founder of JLF Strategy & Communications, Jessica has provided strategic communications and business counsel to mission-driven organizations working at the intersection of healthcare and technology, including Parabilis Medicines, Recursion Pharmaceuticals, the Gates Medical Research Institute, the 120/80 PR Group, and others.

Previously, Jessica served as Global Communications Leader for Data Science & Precision Medicine at Johnson & Johnson Innovative Medicine, where she led enterprise-wide efforts to position J&J as a leader in applying AI, machine learning, and digital health to revolutionize drug discovery, development, and delivery. Her work spanned therapeutic areas—including oncology, immunology, neuroscience, and more—across both R&D and commercial functions and included executive communications, investor engagement, media relations, and cross-functional storytelling initiatives.

Earlier at J&J, Jessica supported the company’s Global Public Health division, where she led communications across a portfolio of products and programs focused on addressing HIV/AIDS, tuberculosis, mental health, and neglected tropical diseases in low- and middle-income countries. Her efforts helped elevate J&J’s public health leadership and advance narratives around access, equity, and global innovation.

Prior to J&J, Jessica spent nearly a decade at Global Health Strategies, a boutique agency specializing in global health and development. She led major campaigns for the Bill & Melinda Gates Foundation, the World Health Organization, and others—and opened the firm’s first office in Africa, expanding its presence and partnerships across the continent.

She holds a B.A. from Duke University, where she studied political science and international relations, African studies, and global health. Jessica lives in New York City with her partner, Cody, and their Tibetan Spaniel, Arley. Outside of work, she enjoys trying new restaurants, traveling, and tackling the NYT Crossword and Spelling Bee.

Kim Fox is a senior healthcare communications leader with more than 30 years of experience shaping global and U.S. strategies across pharmaceutical, biotech, media, and public relations organizations. She is currently Head of Corporate Communications & Patient Advocacy at Legend Biotech and before that, served as Vice President of Communications at Milestone Pharmaceuticals, where she led corporate, product, and investor communications to support the company’s growth and clinical milestones. Previously, at Bristol Myers Squibb, she advanced the company’s global people strategy as Executive Director of Corporate Culture & Enterprise Communications. Earlier, as a Communications Leader at Johnson & Johnson, she built employee engagement and strengthened public trust in the company’s scientific and bioethical leadership.

Kim’s career spans leadership roles at Everyday Health, Sanofi, Novartis, and top communications agencies, with expertise in cardiology, oncology, and gastrointestinal therapeutic areas, as well as corporate reputation, issues management, and digital engagement. Passionate about advancing women’s leadership and education, she has served on the boards of the Healthcare Businesswomen’s Association and Summit Educational Foundation. She holds a BA in English from the University of Rochester.